# AUSTEDO (deutetrabenazine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/deutetrabenazine

> The FDA approved AUSTEDO (deutetrabenazine), sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), on Jul 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AUSTEDO (deutetrabenazine) |
| Codes |  |
| Sponsor | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) https://sec-api.dev/companies/teva/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### May 27, 2016: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA208082_20160527.pdf%22

### April 3, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208082 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170403, review_priority STANDARD; sponsor_name TEVA BRANDED PHARM; product AUSTEDO (DEUTETRABENAZINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208082%22

### August 30, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209885 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20170830, review_priority PRIORITY; sponsor_name TEVA BRANDED PHARM; product AUSTEDO (DEUTETRABENAZINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209885%22

### June 24, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208082 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20210624, review_priority PRIORITY; sponsor_name TEVA BRANDED PHARM; product AUSTEDO (DEUTETRABENAZINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208082%22

### February 17, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-29, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216354 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230217, review_priority STANDARD; sponsor_name TEVA; product AUSTEDO XR (DEUTETRABENAZINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216354%22
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-000462): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007054): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-004974): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-002796): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007000): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-004808): "AUSTEDO XR (deutetrabenazine) extended-release tablets were approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002849): "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000493): "AUSTEDO XR (deutetrabenazine) extended-release tablets were approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm

### May 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-05-07, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in doses of 18 mg in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-000462): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg dose in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007054): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-004974): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-002796): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in doses of 18 mg in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007000): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in a 18 mg dose in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-004808): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002849): "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024." https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/exh_991.htm

### Jul 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-01-29, last confirmed 2025-01-29.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000493): "In July 2024, the FDA approved the 18 mg dosage for AUSTEDO XR, making it a one pill, once-daily option for all available doses." https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/deutetrabenazine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AUSTEDO (deutetrabenazine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/deutetrabenazine

```bibtex
@misc{secapidev_pdufa_deutetrabenazine_20261116,
  title        = {AUSTEDO (deutetrabenazine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/deutetrabenazine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_deutetrabenazine_20261116","title":"AUSTEDO (deutetrabenazine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/deutetrabenazine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
